233 related articles for article (PubMed ID: 28264810)
1. Promoter Methylation Modulates Indoleamine 2,3-Dioxygenase 1 Induction by Activated T Cells in Human Breast Cancers.
Noonepalle SK; Gu F; Lee EJ; Choi JH; Han Q; Kim J; Ouzounova M; Shull AY; Pei L; Hsu PY; Kolhe R; Shi F; Choi J; Chiou K; Huang TH; Korkaya H; Deng L; Xin HB; Huang S; Thangaraju M; Sreekumar A; Ambs S; Tang SC; Munn DH; Shi H
Cancer Immunol Res; 2017 Apr; 5(4):330-344. PubMed ID: 28264810
[TBL] [Abstract][Full Text] [Related]
2. DNA methylation of indoleamine 2,3-dioxygenase 1 (IDO1) in head and neck squamous cell carcinomas correlates with IDO1 expression, HPV status, patients' survival, immune cell infiltrates, mutational load, and interferon γ signature.
Sailer V; Sailer U; Bawden EG; Zarbl R; Wiek C; Vogt TJ; Dietrich J; Loick S; Grünwald I; Toma M; Golletz C; Gerstner A; Kristiansen G; Bootz F; Scheckenbach K; Landsberg J; Dietrich D
EBioMedicine; 2019 Oct; 48():341-352. PubMed ID: 31628024
[TBL] [Abstract][Full Text] [Related]
3. Salinomycin promotes T-cell proliferation by inhibiting the expression and enzymatic activity of immunosuppressive indoleamine-2,3-dioxygenase in human breast cancer cells.
Ebokaiwe AP; Njoya EM; Sheng Y; Zhang Z; Li S; Zhou Z; Qiang Z; Peng T; Hussein AA; Zhang G; Lu X; Li L; Wang F
Toxicol Appl Pharmacol; 2020 Oct; 404():115203. PubMed ID: 32822738
[TBL] [Abstract][Full Text] [Related]
4. Indoleamine 2, 3-dioxygenase 1 promoter hypomethylation is associated with poor prognosis in patients with esophageal cancer.
Kiyozumi Y; Baba Y; Okadome K; Yagi T; Ogata Y; Eto K; Hiyoshi Y; Ishimoto T; Iwatsuki M; Iwagami S; Miyamoto Y; Yoshida N; Watanabe M; Baba H
Cancer Sci; 2019 Jun; 110(6):1863-1871. PubMed ID: 31012515
[TBL] [Abstract][Full Text] [Related]
5. GD2 redirected CAR T and activated NK-cell-mediated secretion of IFNγ overcomes MYCN-dependent IDO1 inhibition, contributing to neuroblastoma cell immune escape.
Caforio M; Sorino C; Caruana I; Weber G; Camera A; Cifaldi L; De Angelis B; Del Bufalo F; Vitale A; Goffredo BM; De Vito R; Fruci D; Quintarelli C; Fanciulli M; Locatelli F; Folgiero V
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33737337
[TBL] [Abstract][Full Text] [Related]
6. MUC1-C integrates activation of the IFN-γ pathway with suppression of the tumor immune microenvironment in triple-negative breast cancer.
Yamashita N; Long M; Fushimi A; Yamamoto M; Hata T; Hagiwara M; Bhattacharya A; Hu Q; Wong KK; Liu S; Kufe D
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33495298
[TBL] [Abstract][Full Text] [Related]
7. Suppression of indoleamine-2,3-dioxygenase 1 expression by promoter hypermethylation in ER-positive breast cancer.
Dewi DL; Mohapatra SR; Blanco Cabañes S; Adam I; Somarribas Patterson LF; Berdel B; Kahloon M; Thürmann L; Loth S; Heilmann K; Weichenhan D; Mücke O; Heiland I; Wimberger P; Kuhlmann JD; Kellner KH; Schott S; Plass C; Platten M; Gerhäuser C; Trump S; Opitz CA
Oncoimmunology; 2017; 6(2):e1274477. PubMed ID: 28344890
[TBL] [Abstract][Full Text] [Related]
8. An Autocrine Cytokine/JAK/STAT-Signaling Induces Kynurenine Synthesis in Multidrug Resistant Human Cancer Cells.
Campia I; Buondonno I; Castella B; Rolando B; Kopecka J; Gazzano E; Ghigo D; Riganti C
PLoS One; 2015; 10(5):e0126159. PubMed ID: 25955018
[TBL] [Abstract][Full Text] [Related]
9. In vitro cytokine licensing induces persistent permissive chromatin at the Indoleamine 2,3-dioxygenase promoter.
Rovira Gonzalez YI; Lynch PJ; Thompson EE; Stultz BG; Hursh DA
Cytotherapy; 2016 Sep; 18(9):1114-28. PubMed ID: 27421739
[TBL] [Abstract][Full Text] [Related]
10. GCH1 induces immunosuppression through metabolic reprogramming and IDO1 upregulation in triple-negative breast cancer.
Wei JL; Wu SY; Yang YS; Xiao Y; Jin X; Xu XE; Hu X; Li DQ; Jiang YZ; Shao ZM
J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34281987
[TBL] [Abstract][Full Text] [Related]
11. A comprehensive analysis of IDO1 expression with tumour-infiltrating immune cells and mutation burden in gynaecologic and breast cancers.
Feng X; Tang R; Zhang R; Wang H; Ji Z; Shao Y; Wang S; Zhong T; Gu Y; Meng J
J Cell Mol Med; 2020 May; 24(9):5238-5248. PubMed ID: 32227579
[TBL] [Abstract][Full Text] [Related]
12. Immune Checkpoint Profiles in Luminal B Breast Cancer (Alliance).
Anurag M; Zhu M; Huang C; Vasaikar S; Wang J; Hoog J; Burugu S; Gao D; Suman V; Zhang XH; Zhang B; Nielsen T; Ellis MJ
J Natl Cancer Inst; 2020 Jul; 112(7):737-746. PubMed ID: 31665365
[TBL] [Abstract][Full Text] [Related]
13. IDO1 Expression in Ovarian Cancer Induces PD-1 in T Cells
Amobi-McCloud A; Muthuswamy R; Battaglia S; Yu H; Liu T; Wang J; Putluri V; Singh PK; Qian F; Huang RY; Putluri N; Tsuji T; Lugade AA; Liu S; Odunsi K
Front Immunol; 2021; 12():678999. PubMed ID: 34025677
[TBL] [Abstract][Full Text] [Related]
14. Signal Transducer and Activator of Transcription 1 Plays a Pivotal Role in RET/PTC3 Oncogene-induced Expression of Indoleamine 2,3-Dioxygenase 1.
Moretti S; Menicali E; Nucci N; Voce P; Colella R; Melillo RM; Liotti F; Morelli S; Fallarino F; Macchiarulo A; Santoro M; Avenia N; Puxeddu E
J Biol Chem; 2017 Feb; 292(5):1785-1797. PubMed ID: 27994058
[TBL] [Abstract][Full Text] [Related]
15. An epigenetic mechanism for high, synergistic expression of indoleamine 2,3-dioxygenase 1 (IDO1) by combined treatment with zebularine and IFN-γ: potential therapeutic use in autoimmune diseases.
Xue ZT; Sjögren HO; Salford LG; Widegren B
Mol Immunol; 2012 Jun; 51(2):101-11. PubMed ID: 22424783
[TBL] [Abstract][Full Text] [Related]
16. Curcumin suppresses the induction of indoleamine 2,3-dioxygenase by blocking the Janus-activated kinase-protein kinase Cdelta-STAT1 signaling pathway in interferon-gamma-stimulated murine dendritic cells.
Jeong YI; Kim SW; Jung ID; Lee JS; Chang JH; Lee CM; Chun SH; Yoon MS; Kim GT; Ryu SW; Kim JS; Shin YK; Lee WS; Shin HK; Lee JD; Park YM
J Biol Chem; 2009 Feb; 284(6):3700-8. PubMed ID: 19075017
[TBL] [Abstract][Full Text] [Related]
17. Indoleamine 2,3-dioxygenase 1 (IDO1) is up-regulated in thyroid carcinoma and drives the development of an immunosuppressant tumor microenvironment.
Moretti S; Menicali E; Voce P; Morelli S; Cantarelli S; Sponziello M; Colella R; Fallarino F; Orabona C; Alunno A; de Biase D; Bini V; Mameli MG; Filetti S; Gerli R; Macchiarulo A; Melillo RM; Tallini G; Santoro M; Puccetti P; Avenia N; Puxeddu E
J Clin Endocrinol Metab; 2014 May; 99(5):E832-40. PubMed ID: 24517146
[TBL] [Abstract][Full Text] [Related]
18. Subtype-specific overexpression of the Rac-GEF P-REX1 in breast cancer is associated with promoter hypomethylation.
Barrio-Real L; Benedetti LG; Engel N; Tu Y; Cho S; Sukumar S; Kazanietz MG
Breast Cancer Res; 2014 Sep; 16(5):441. PubMed ID: 25248717
[TBL] [Abstract][Full Text] [Related]
19. Indoleamine-2,3-dioxygenase-1 expression predicts poorer survival and up-regulates ZEB2 expression in human early stage bladder cancer.
Tsai YS; Jou YC; Tsai HT; Cheong IS; Tzai TS
Urol Oncol; 2019 Nov; 37(11):810.e17-810.e27. PubMed ID: 31253481
[TBL] [Abstract][Full Text] [Related]
20. Myeloid-derived suppressor cells suppress antitumor immune responses through IDO expression and correlate with lymph node metastasis in patients with breast cancer.
Yu J; Du W; Yan F; Wang Y; Li H; Cao S; Yu W; Shen C; Liu J; Ren X
J Immunol; 2013 Apr; 190(7):3783-97. PubMed ID: 23440412
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
